Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence.

Marino Gammazza, Antonella

Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence. [electronic resource] - Cancer letters 01 2017 - 75-86 p. digital

Publication Type: Journal Article

1872-7980

10.1016/j.canlet.2016.10.045 doi


Acetylation
Antibiotics, Antineoplastic--pharmacology
Apoptosis--drug effects
Carcinoma, Mucoepidermoid--drug therapy
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Survival--drug effects
Cellular Senescence--drug effects
Chaperonin 60--genetics
Chaperonins--metabolism
Cyclin-Dependent Kinase Inhibitor p21--metabolism
Dose-Response Relationship, Drug
Doxorubicin--pharmacology
G2 Phase Cell Cycle Checkpoints--drug effects
Histones--metabolism
Humans
Lung Neoplasms--drug therapy
Mitochondrial Proteins--genetics
Protein Binding
Protein Processing, Post-Translational--drug effects
Proteolysis
Signal Transduction--drug effects
Tumor Suppressor Protein p53--metabolism
Ubiquitination